TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05703100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental exercise test
Description: Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental exercise test under hyperthermia
Description: Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental exercise test under glycogen depletion
Description: Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
Study: NCT04789096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral tablet
Study: NCT05632146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suturing
Description: In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suturing
Description: In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted X suturing
Description: In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted X suturing
Description: In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
Study: NCT06549699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meal Program with Traditional Navajo Foods
Description: Patients will receive medically-tailored meals incorporating local traditional Navajo foods
Study: NCT06580262

Intervention type: OTHER
Intervention: Routine care
Description: The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge.
Study: NCT05028725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophaCap Sponge
Description: Non-invasive strategy to sample esophageal tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophaCap Sponge
Description: Non-invasive strategy to sample esophageal tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophaCap Sponge
Description: Non-invasive strategy to sample esophageal tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoCAN assay
Description: Biomarker Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoCAN assay
Description: Biomarker Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoCAN assay
Description: Biomarker Test
Study: NCT04347551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity/low amplitude cervical spine manipulation
Description: The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High velocity/low amplitude cervical spine manipulation
Description: The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
Study: NCT05333250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05728177

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Aromatherapy
Description: Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Inhalation Aromatherapy
Description: Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care.
Study: NCT06549699

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care plus healthy recipes provided
Study: NCT04771598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise with the phone application
Description: 1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home.

Intervention type: OTHER
Group type: OTHER
Intervention: Breathing exercise
Description: 1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
Study: NCT06129604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495
Description: Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
Study: NCT06170580

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional carotid duplex measurement
Study: NCT05901935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c injection, 3.0 mg/kg, Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV, 6 mg/kg, D1, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: IV, 25 mg/m\^2，D1、D8，Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: PO 1000 mg/m\^2, bid, D1-D14, Q3W
Study: NCT06170580

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional carotid duplex measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging using plane wave imaging
Description: Ultrasound-based flow imaging using plane wave imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging using plane wave imaging
Description: Ultrasound-based flow imaging using plane wave imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging using cascaded wave imaging
Description: Ultrasound-based flow imaging using cascaded wave imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging using cascaded wave imaging
Description: Ultrasound-based flow imaging using cascaded wave imaging
Study: NCT05472129

Intervention type: OTHER
Intervention: self-administered questionnaires
Description: The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained

Intervention type: OTHER
Intervention: self-administered questionnaires
Description: The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
Study: NCT06400849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy alone of the upper or lower limbs
Description: Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy and crompression of the upper or lower limbs
Description: Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
Study: NCT05610501

Intervention type: PROCEDURE
Intervention: Ultrasound guided tru-cut biopsy
Description: Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
Study: NCT05163496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (Usona Institute)
Description: PAP + psilocybin 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active placebo
Description: PAP + niacin 250mg
Study: NCT04431258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
Study: NCT06534619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rocabado exercises
Description: 6 Rocabado exercises 6 Reps each.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rocabado exercises
Description: 6 Rocabado exercises 6 Reps each.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland oscillatory mobilizations
Description: Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides
Study: NCT04894422

Intervention type: OTHER
Intervention: Observational intervention
Description: Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.

Intervention type: OTHER
Intervention: Observational intervention
Description: Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.

Intervention type: OTHER
Intervention: Observational intervention
Description: Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
Study: NCT05585359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: injectable platelet rich fibrin augmented with Vitamin C
Description: According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin augmented with Vitamin C
Description: According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
Study: NCT05198128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium intravenous infsuion
Description: intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: 0.9 % saline
Study: NCT05312762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaxioCel
Description: Microfiber wound dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AquaCel Extra
Description: Hydrofiber dressing
Study: NCT06068855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injections
Study: NCT06496490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: HER2 dual-antibody-drug Conjugate (ADC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection combined with Benmelstobart injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
Study: NCT05890599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education courses are conducted on-site once a week for 90 minutes over 12 weeks by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
Study: NCT05940532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugemalimab and Chemotherapy
Description: Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years.
Study: NCT05418699

Intervention type: DEVICE
Intervention: closed-loop insulin pump
Description: Follow up of patients with real-time closed-loop insulin delivery systems
Study: NCT06350032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservative-free parenteral treprostinil
Description: Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
Study: NCT04749030

Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation (FMT) capsules
Description: The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
Study: NCT06305949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation
Description: transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side